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Dudley White. Boston, MA: Harvard University Press, 1986.ReplyI would like to thank Dr. Taegtmeyer very much indeed for his
ﬁne letter concerning our recent publication in the Journal (1).
I appreciate very much his comments and his personal experiences
in the twilight of the darkest period of Germany’s history. I am
chairman of the Task Force on History of Cardiology in
Germany; we are preparing a comprehensive report on the
political involvement of German and Austrian cardiologists
during the so-called Third Reich. I would be glad to inform
Dr. Taegtmeyer about our ongoing efforts nearer the time of
publication.
Once again, I thank Dr. Taegtmeyer for his interest in our work.
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Effect and the Accuracy of
Fractional Flow Reserve
We read with great interest the paper by Wittfeldt et al. (1), which
demonstrated that the novel adenosine diphosphate receptor
P2Y12 antagonist, ticagrelor, augments the adenosine-inducedincrease in coronary blood ﬂow velocity in healthy volunteers.
Ticagrelor has been shown to improve clinical outcomes in patients
with acute coronary syndromes compared with clopidogrel (2), and
its use is now recommended as ﬁrst-line therapy by international
guidelines (3,4).
The ﬁndings of this study may have important clinical impli-
cations in those patients who are taking ticagrelor and subsequently
require measurement of fractional ﬂow reserve (FFR) to assess the
hemodynamic signiﬁcance of coronary lesions. Accurate FFR
measurement requires maximal coronary hyperemia, and it is
recommended that this should be achieved with a continuous
intravenous infusion of adenosine at a rate of 140 mg/kg/min (5).
Although most studies have been performed using a maximum
infusion rate of 140 mg/kg/min, this may not achieve maximal
hyperemia in some patients. It has been suggested that higher doses
may be required to obtain accurate results (6).
Because ticagrelor has been shown to enhance adenosine-
induced vasodilatation, the degree of hyperemia obtained with
adenosine infusion may be greater than that obtained in patients
taking clopidogrel. This would lead to a lower FFR and a more
accurate reﬂection of the true functional signiﬁcance of a coronary
lesion.
The increasing use of ticagrelor in the future may also allow for the
routine use of intracoronary adenosine, because it has previously
been shown to be less reliable and more problematic than intrave-
nous infusion (6). If this is the case, the adoption of this more
simpliﬁed method may translate into an increased utilization of FFR
as a valuable investigative procedure with subsequent improved
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